FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111723930> ?p ?o ?g. }

• W2111723930 endingPage "849" @default.
• W2111723930 startingPage "843" @default.
• W2111723930 abstract "Glycopeptide antibiotics are used extensively in the empirical treatment of febrile patients with neutropenia. To come to a more rational and restricted application of these expensive drugs and to reduce the risk of emergence of resistance, we carried out a prospective, double-blinded, placebo-controlled single-centre study to investigate whether the addition of teicoplanin improved the outcome of neutropenic patients who remained febrile after 72–96 h of imipenem monotherapy. Patients with known infections caused by imipenem-resistant microorganisms were excluded. From the 114 evaluable episodes (out of a total of 125) in 105 patients who met the eligibility criteria, 56 episodes were randomized to receive teicoplanin and 58 to placebo. At 72 h after the start of the assigned intervention, 52 (45.6%) of the patients were afebrile; at the end of the aplastic phase, 10 (8.8%) had succumbed. There was no difference between the two study arms. When febrile episodes were subdivided between microbiologically documented infections, clinically documented infections and fevers of unknown origin, again no significant differences were observed. With the exception of methicillin-resistant bacteria, Gram-positive infections seemed to respond well to imipenem monotherapy. It is concluded that the addition of teicoplanin on empirical grounds, i.e. for persistent fever only, is not necessary and that the use of glycopeptides should be restricted to well-defined clinical situations where methicillin-resistant bacteria are involved. Furthermore, it seems that many neutropenic patients respond slowly over more than 72–96 h even when they are treated with antibacterial drugs such as imipenem that are effective against the causative microorganism." @default.
• W2111723930 created "2016-06-24" @default.
• W2111723930 creator A5011660944 @default.
• W2111723930 creator A5029392712 @default.
• W2111723930 creator A5029655746 @default.
• W2111723930 creator A5046872067 @default.
• W2111723930 creator A5070475809 @default.
• W2111723930 date "2000-06-01" @default.
• W2111723930 modified "2023-09-25" @default.
• W2111723930 title "A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy" @default.
• W2111723930 cites W1506521422 @default.
• W2111723930 cites W1568219033 @default.
• W2111723930 cites W1852266951 @default.
• W2111723930 cites W1977790552 @default.
• W2111723930 cites W1990753471 @default.
• W2111723930 cites W2001101162 @default.
• W2111723930 cites W2004595934 @default.
• W2111723930 cites W2023957234 @default.
• W2111723930 cites W2041640387 @default.
• W2111723930 cites W2043977100 @default.
• W2111723930 cites W2044363049 @default.
• W2111723930 cites W2045800654 @default.
• W2111723930 cites W2051489716 @default.
• W2111723930 cites W2057587497 @default.
• W2111723930 cites W2062951145 @default.
• W2111723930 cites W2073076515 @default.
• W2111723930 cites W2082816719 @default.
• W2111723930 cites W2089404143 @default.
• W2111723930 cites W2108818954 @default.
• W2111723930 cites W2114208000 @default.
• W2111723930 cites W2117312545 @default.
• W2111723930 cites W2131721390 @default.
• W2111723930 cites W2148244365 @default.
• W2111723930 cites W2156783478 @default.
• W2111723930 cites W2163195044 @default.
• W2111723930 cites W4238546275 @default.
• W2111723930 doi "https://doi.org/10.1093/jac/45.6.843" @default.
• W2111723930 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10837439" @default.
• W2111723930 hasPublicationYear "2000" @default.
• W2111723930 type Work @default.
• W2111723930 sameAs 2111723930 @default.
• W2111723930 citedByCount "58" @default.
• W2111723930 countsByYear W21117239302012 @default.
• W2111723930 countsByYear W21117239302014 @default.
• W2111723930 countsByYear W21117239302015 @default.
• W2111723930 countsByYear W21117239302016 @default.
• W2111723930 countsByYear W21117239302017 @default.
• W2111723930 countsByYear W21117239302021 @default.
• W2111723930 countsByYear W21117239302023 @default.
• W2111723930 crossrefType "journal-article" @default.
• W2111723930 hasAuthorship W2111723930A5011660944 @default.
• W2111723930 hasAuthorship W2111723930A5029392712 @default.
• W2111723930 hasAuthorship W2111723930A5029655746 @default.
• W2111723930 hasAuthorship W2111723930A5046872067 @default.
• W2111723930 hasAuthorship W2111723930A5070475809 @default.
• W2111723930 hasBestOaLocation W21117239301 @default.
• W2111723930 hasConcept C126322002 @default.
• W2111723930 hasConcept C137610392 @default.
• W2111723930 hasConcept C141071460 @default.
• W2111723930 hasConcept C142724271 @default.
• W2111723930 hasConcept C168563851 @default.
• W2111723930 hasConcept C204787440 @default.
• W2111723930 hasConcept C27081682 @default.
• W2111723930 hasConcept C2776694085 @default.
• W2111723930 hasConcept C2776703206 @default.
• W2111723930 hasConcept C2777063308 @default.
• W2111723930 hasConcept C2778850193 @default.
• W2111723930 hasConcept C2778980435 @default.
• W2111723930 hasConcept C2779375183 @default.
• W2111723930 hasConcept C2779489039 @default.
• W2111723930 hasConcept C2779631663 @default.
• W2111723930 hasConcept C3019249092 @default.
• W2111723930 hasConcept C501593827 @default.
• W2111723930 hasConcept C523546767 @default.
• W2111723930 hasConcept C54355233 @default.
• W2111723930 hasConcept C71924100 @default.
• W2111723930 hasConcept C86803240 @default.
• W2111723930 hasConcept C89423630 @default.
• W2111723930 hasConcept C94665300 @default.
• W2111723930 hasConceptScore W2111723930C126322002 @default.
• W2111723930 hasConceptScore W2111723930C137610392 @default.
• W2111723930 hasConceptScore W2111723930C141071460 @default.
• W2111723930 hasConceptScore W2111723930C142724271 @default.
• W2111723930 hasConceptScore W2111723930C168563851 @default.
• W2111723930 hasConceptScore W2111723930C204787440 @default.
• W2111723930 hasConceptScore W2111723930C27081682 @default.
• W2111723930 hasConceptScore W2111723930C2776694085 @default.
• W2111723930 hasConceptScore W2111723930C2776703206 @default.
• W2111723930 hasConceptScore W2111723930C2777063308 @default.
• W2111723930 hasConceptScore W2111723930C2778850193 @default.
• W2111723930 hasConceptScore W2111723930C2778980435 @default.
• W2111723930 hasConceptScore W2111723930C2779375183 @default.
• W2111723930 hasConceptScore W2111723930C2779489039 @default.
• W2111723930 hasConceptScore W2111723930C2779631663 @default.
• W2111723930 hasConceptScore W2111723930C3019249092 @default.
• W2111723930 hasConceptScore W2111723930C501593827 @default.
• W2111723930 hasConceptScore W2111723930C523546767 @default.
• W2111723930 hasConceptScore W2111723930C54355233 @default.

• next